- Neuro-All - University of Manitoba Mailing Lists

ATTENTION STUDENTS: DREAM Seminar Series - Thursday March 22
by Crystal May Acosta 19 Mar '18

19 Mar '18

Good morning! Students you are invited to a career development workshop on Thursday March 22. See details below and attachments for more info. Contact Stephanie Kereliuk if you have questions: umkereli(a)myumanitoba.ca Crystal ------------------------------------------------------------------------------------------- Crystal Acosta B.Sc., M.Sc., PhD. Student Pharmacology & Therapeutics University of Manitoba St. Boniface Hospital Albrechtsen Research Centre R2032 - 351 Taché Avenue Winnipeg, MB, R2H 2A6 Kleysen Institute for Advanced Medicine SR452 - 710 William Avenue Winnipeg, MB, R3E 0Z3 P: (204) 997-1985<tel:204%29%20997-1985> E: umacostc(a)myumanitoba.ca<mailto:umacostc@myumanitoba.ca> ________________________________ From: Stephanie Kereliuk Sent: Monday, March 19, 2018 10:22 AM To: Crystal May Acosta; Adam Hogan-Cann Subject: Fwd: DREAM Seminar Series - Thursday March 22 Hey guys! On Thursday March 22 the DREAM Trainees will be hosting a career development based seminar with Thermo Fisher representatives Shantel Gushue and Brett Dalman. It will take place from 3-4pm in 500 JBRC (5th floor CHRIM) Pharmacology students and other members of KIAM are invited to attend. Could you please circulate the e-mail below/poster to MNN/neuroscience/KIAM students/any one who would be interested? Thanks! Stephanie Begin forwarded message: From: DREAM Trainees <dreamtrainees(a)gmail.com<mailto:dreamtrainees@gmail.com>> Subject: DREAM Seminar Series - Thursday March 22 Date: March 19, 2018 at 10:08:31 AM CDT To: undisclosed-recipients:; Hi everyone, On Thursday March 22 we will have DREAM Seminar Series. As always, it will take place from 3-4pm in 500JBRC and everyone is welcome to attend! Shantel & Brett from Thermo Fisher Scientific will be here to give us a carrer development based talk and they will present on the skills required to work in sales and how to transition from working in the lab to a sales role. There biographies are included below: Brett Dalman, BSc. Brett graduated with a Bachelor of Science, Major Microbiology with a minor in zoology in the Co-op Program from the University of Manitoba. During university, she participated in the co-op program gaining experience with Miraculins (a biotech company working on cancer), and the Canadian Food Inspection Agency (CFIA). Upon graduation, she continued to work at the CFIA as a permanent technician working with high containment viruses for research and diagnostics applications. In 2010, she began the next stage in her career and became a Sales Representative, for the distribution company VWR, dealing with a variety of accounts and product lines. In 2014, she was approached to join a more specialized company as a Territory Manager for Thermo Fisher Scientific where she relies on her scientific degree to better support research labs. Shantel Gushue, MSc. Shantel Gushue graduated with her Bachelor of Science Degree as a ‘Student of Distinction’ from the University of Winnipeg in 2008. Shortly thereafter, she pursued graduate school at the University of Manitoba in the Department of Medical Microbiology and Infectious Disease. After working approximately 10 months as a Clinical Research Coordinator at the Children’s Hospital Research Institute of Manitoba, she landed a position with Fisher Scientific as an Account Manager. Her primary focus is to sell laboratory supplies, chemicals, and equipment into pharmaceutical, clinical, industrial, academic, and agricultural accounts. Although she initially had little experience in the area of sales and business, she has been very successful and continues to drive sales for the company as well as create long lasting partnerships with both colleagues and customers. The rest of the March Schedule is as follows: Thursday March 29 - Work in Progress by Dr. Kozeta Miliku (Human milk oligosaccharides, food sensitization and asthma in early childhood) (3-4PM 500JBRC) If you are interested in presenting a seminar (journal article, update on your work, other topic of interest) please respond to this e-mail. April 5th and May dates are available. Also please don't forget to forward any updates or items you would like included in the DREAM Trainees Newsletter to this e-mail. -- Connect with us on Twitter @DREAM_trainees & #DREAMwpg [https://drive.google.com/uc?id=1m3ak0u_Ks9lTI_wGOxDapSzRjshBH4CL&export=dow…]

1 0

MNN Seminar | Dr. Soheila Karimi - Mar 23rd @ 9am Px236/238 Psychealth Bldg.
by Manitoba Neuroscience Network 19 Mar '18

19 Mar '18

cid:image001.jpg@01D158FE.B69B8D00 S E M I N A R & V I S I T I N G S P E A K E R S E R I E S D AT E Friday, March 23rd, 2018 9 am L O C AT I O N 236/238 PsycHealthBldg. S P E A K E R <http://umanitoba.ca/faculties/health_sciences/medicine/units/physiology/con tacts/karimi.html> Dr. Soheila Karimi Associate Professor Department of Physiology & Pathophysiology Senior Scientist, Regenerative Medicine Program Principal Investigator, Spinal Cord Research Center T O P I C Emerging therapeutic targets for spinal cord injury and Multiple Sclerosis B I O Dr. Soheila Karimi is an Associate Professor in the Department of Physiology and Pathophysiology, and the Regenerative Medicine Program, in the Rady Faculty of Health Sciences, at the University of Manitoba. Soheila has had a long-term interest in neural repair and regeneration with a focus on therapeutic development for spinal cord injury and multiple sclerosis. She received her PhD degree in neurosciences from the University of Saskatchewan in 2001, and then undertook a postdoctoral fellowship in spinal cord injury and stem cell research at the University of Toronto and the Toronto Western Hospital. During her training, Soheila received numerous academic and research awards including a Synthes Award from the American Association of Neurological Surgeons, and postdoctoral fellowships from the Canadian Institutes of Health Research, Ontario Neurotrauma Foundation and the Heart and Stroke Foundation. Her postdoctoral work broke a new ground in spinal cord injury therapeutics by showing that transplantation of neural stem cells can be used therapeutically to promote myelin repair with improved recovery of function in preclinical models. Her seminal work has been instrumental for implementing neural stem cell therapies in human clinical trials that are currently under way. Soheila joined the University of Manitoba in 2010 to help in establishing the Regenerative Medicine Program in Manitoba. Current research in Karimis laboratory focuses on uncovering disease mechanisms and developing regenerative therapies for spinal cord injury and multiple sclerosis. Using drug delivery, stem cell therapy, genetic manipulations and bioengineering approaches, Karimis team have discovered novel targets that play major roles in regulating cell replacement and myelin repair in these conditions. Karimis team have published their discoveries in top-tier journals such as Stem Cells, Nature, J. Neuroscience, GLIA, J. Neuroinflammation. Karimis research program has been supported by concurrent grants from the CIHR, Multiple Sclerosis Society of Canada, NSERC, Canada Foundation for Innovation, Craig H. Neilsen Foundation in the US, Research Manitoba and the Canadian Paraplegic Association. L E A R N I N G O B J E C T I V E S - Provide an overview on neuroinflammation and demyelination, two common mechanisms of spinal cord injury (SCI) and multiple sclerosis (MS). - Discuss novel endogenous regulators of immune response in the injured and diseased spinal cord - Highlight our recent advances in therapeutic development for augmenting oligodendrocyte replacement and myelin repair in CNS demyelination /sent on behalf of Dr. Eftekhar Eftekharpour Coordinator, Seminar & Visiting Speaker Series Manitoba Neuroscience Network E: Eftekhar.Eftekharpour(a)umanitoba.ca Kelly Jorundson Coordinator, Membership & Operations Manitoba Neuroscience Network Email: kjorund(a)sbrc.ca Tel: 204.235.3939 Fax: 204.237.4092 St. Boniface Hospital Albrechtsen Research Centre Room R4046 - 351 Taché Avenue, Winnipeg, MB R2H 2A6 CANADA This email and any attachments may contain confidential, personal and/or privileged information intended for a specific individual and purpose. If you are not the intended recipient, you are hereby notified that any disclosure, copying, retaining, distribution, access, use or modification of the contents of this e-mailed information is strictly prohibited. If you receive this communication in error, please notify the sender immediately and delete or destroy the email message and any attachments or copies. ****************************************** <http://www.manitobaneuroscience.ca/> cid:image003.jpg@01D159B3.9F0B9710 <https://www.facebook.com/manitobaneuroscience/?fref=ts> cid:image007.png@01D29326.7E26D480 <https://www.instagram.com/manitobaneuroscience/> cid:image009.jpg@01D29326.7E26D480 <https://twitter.com/manitobaneuro> cid:image010.png@01D29326.7E26D480

1 0

Dementia Journal Club - March 20th at noon - please post and distribute -
by Manitoba Neuroscience Network 19 Mar '18

19 Mar '18

cid:image001.jpg@01D158FE.B69B8D00 /sent on behalf of Dr. Ben Albensi Everyone is invited to attend. Dementia Journal Club Date: March 20th, 2018 Time: 12 Noon Location: St Boniface Hosp. Res. R1003, 351 Tache Ave, Wpg. Dr. Phil St. John <http://umanitoba.ca/centres/aging/people/130.html> Associate Professor Co-lead Manitoba site investigator, CLSA Section of Geriatrics, Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences; cross appointment, Department of Family Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences Effect of a 24-Month Physical Activity Intervention vs Health Education on Cognitive Outcomes in Sedentary Older Adults The LIFE Randomized Trial Physical activity, cognitive decline, and risk of dementia: 28 year follow-up of Whitehall II cohort study With kind regards, Ben Benedict C. Albensi, PhD, BCMAS, CRQM Professor & Manitoba Dementia Research Chair Max Rady College of Medicine cid:image001.png@01D3B158.2C68F230 Dept. of Pharmacology & Therapeutics Biomedical Engineering Core Member Faculties of Health Sciences, Engineering, & Science Research Affiliate, Centre on Aging Principal Investigator, St. Boniface Hospital Research Everett Endowment Fund Chair Division of Neurodegenerative Disorders (DND) cid:image003.png@01D1B033.4251C1D0 St. Boniface Hospital Research 351 Tache Ave./Lab 4050 Winnipeg, Manitoba R2H 2A6 Canada Tel: 204-235-3942 (office) Tel: 204-235-3941 (lab) Email: balbensi(a)sbrc.ca

1 0

REMINDER: BAW Special Lecture - Dr. Karim Fouad | Thurs. Mar 15 @12noon
by Manitoba Neuroscience Network 15 Mar '18

15 Mar '18

Gentle reminder.today. cid:image001.jpg@01D158FE.B69B8D00 SPECIAL LECTURE: B R A I N A W A R E N E S S W E E K D A T E Thursday, March 15th, 2018 12Noon *Followed by a Trainee Lunch in Rm 636 BMSB L O C A T I O N Rm 626 Basic Sci Bldg. S P E A K E R D R . K A R I M F O UA D C A N A D A R E S E A R C H C H A I R S P I N A L C O R D I N J U R Y T O P I C Promoting plasticity and recovery following spinal cord injury Karim Fouad studied Biology in Germany where he also performed his Graduate studies on motor control of invertebrates. During his time as PDF in Edmonton, with Dr. Pearson he switched to locomotor control in vertebrates, which triggered his interest in neuroplasticity. He expanded his research in the area of injury induced neuroplasticity in the groups of Drs. Schwab and Dietz in Zürich, Switzerland, especially in relation to spinal cord injuries. In 2001 he started his group in at the University of Alberta in Edmonton, where he is now a Professor and Canada Research Chair in the Department of Physical Therapy, in the Faculty of Rehabilitation Medicine. Karim Fouads research focuses on repair of the injured spinal cord. This includes combined treatment approaches to regenerate lost connections but also to rewire spared circuitry. He uses rehabilitative training to study, and enhance mechanisms of neuro plasticity, but also as a tool to promote functional recovery when plasticity is pharmacologically enhanced. Over the last years he developed a more compressive view on plasticity exploring a wide range of changes that occur after spinal injuries, ranging from spasticity, to blood flow and mental health. /sent on behalf of Dr. Eftekhar Eftekharpour Coordinator, Seminar & Visiting Speaker Series Manitoba Neuroscience Network E: Eftekhar.Eftekharpour(a)umanitoba.ca Kelly Jorundson Coordinator, Membership & Operations Manitoba Neuroscience Network Email: kjorund(a)sbrc.ca Tel: 204.235.3939 Fax: 204.237.4092 St. Boniface Hospital Albrechtsen Research Centre Room R4046 - 351 Taché Avenue, Winnipeg, MB R2H 2A6 CANADA This email and any attachments may contain confidential, personal and/or privileged information intended for a specific individual and purpose. If you are not the intended recipient, you are hereby notified that any disclosure, copying, retaining, distribution, access, use or modification of the contents of this e-mailed information is strictly prohibited. If you receive this communication in error, please notify the sender immediately and delete or destroy the email message and any attachments or copies. ****************************************** <http://www.manitobaneuroscience.ca/> cid:image003.jpg@01D159B3.9F0B9710 <https://www.facebook.com/manitobaneuroscience/?fref=ts> cid:image007.png@01D29326.7E26D480 <https://www.instagram.com/manitobaneuroscience/> cid:image009.jpg@01D29326.7E26D480 <https://twitter.com/manitobaneuro> cid:image010.png@01D29326.7E26D480

1 0

TODAY | BAW SPECIAL EVENT - In Conversation with Dr. Pierre Marquet
by Kae Normandeau 14 Mar '18

14 Mar '18

[cid:image001.jpg@01D158FE.B69B8D00] B R A I N A W A R E N E S S W E E K SPECIAL EVENT: D A T E Wednesday, March 14th, 2018 7:00pm L O C A T I O N McNally Robinson Bookstore 4000-1120 Grant Avenue IN CONVERSATION WITH DR. PIERRE MARQUET C A N A D A EXCELLENCE R E S E A R C H C H A I R NEUROPHOTONICS T O P I C Identification of a childhood risk syndrome of major psychiatric diseases: a step towards their prevention. Psychiatrist, Pierre Marquet also holds a Master of physical engineering from Ecole Polytechnique Fédérale de Lausanne, Switzerland and an M.D./Ph.D. in neurophotonics from University of Lausanne. Recognized worldwide for his pioneering work on digital holographic microscopy, he is a professor of psychiatry at Université Laval and the chairholder of the CERC in Neurophotonics. He is also the director of the International Joint Research Unit (IJRU) in neurodevelopment and child psychiatry. The goal of this IJRU is to identify new risk biomarkers and endophenotypes to define childhood risk syndromes of major psychiatric disorders including schizophrenia, bipolar disorders and major depression disorder with the help of neurophotonics tools. He is the author or co-author of more than 140 scientific publications (6500 citations, h-index 36), of many patents and is the co-founder of three technological start-up companies. Kae Normandeau Administrative Manager Neuroscience Research Program SR440 KIAM Building P: 204-318-2569 E: kae.normandeau(a)umanitoba.ca<mailto:kae.normandeau@umanitoba.ca> This email and any attachments may contain confidential, personal and/or privileged information intended for a specific individual and purpose. If you are not the intended recipient, you are hereby notified that any disclosure, copying, retaining, distribution, access, use or modification of the contents of this e-mailed information is strictly prohibited. If you receive this communication in error, please notify the sender immediately and delete or destroy the email message and any attachments or copies. ****************************************** [cid:image003.jpg@01D159B3.9F0B9710]<http://www.manitobaneuroscience.ca/> [cid:image007.png@01D29326.7E26D480]<https://www.facebook.com/manitobaneuroscience/?fref=ts> [cid:image009.jpg@01D29326.7E26D480] <https://www.instagram.com/manitobaneuroscience/> [cid:image010.png@01D29326.7E26D480] <https://twitter.com/manitobaneuro>

1 0

TODAY | BAW Special Lecture - Dr. Pierre Marquet
by Kae Normandeau 14 Mar '18

14 Mar '18

[cid:image001.jpg@01D158FE.B69B8D00] SPECIAL LECTURE: B R A I N A W A R E N E S S W E E K D A T E Wednesday, March 14th, 2018 12Noon *Followed by a Trainee Lunch in SR415, KIAM L O C A T I O N Theatre C, BMSB S P E A K E R D R . PIERRE MARQUET C A N A D A EXCELLENCE R E S E A R C H C H A I R NEUROPHOTONICS T O P I C Neurophotonics to Intercept the Emergence of Major Psychiatric Disorders Major psychiatric disorders (MPDs) including psychosis and mood disorders affect *4% of the population. MPDs have chronic courses since their diagnoses, solely based on clinical symptoms, are very late and thus better treatments are only palliative. The successful development of early treatment and primary prevention is largely impeded by the lack of reliable risk biomarkers or endophenotypes (B/Es). This is a critical issue since MPDs have a neurodevelopmental origin and early intervention can improve outcomes. >From a developmental standpoint, the identification of B/Es in patients with MPDs and in their offspring at genetic risk will play a pivotal role in the definition of childhood risk syndromes and their corresponding abnormal trajectories. This approach is particularly relevant given that high-risk children carry many of the indicators of brain dysfunctions that adult patients have. Within this framework, I will present how the development of new multimodal optical imaging techniques in combination with stem cell technologies, including human induced pluripotent stem cells approaches, can contribute to identifying new cellular B/Es relevant both to define childhood risk syndromes and to determine cellular processes likely to be involved in the pathogenesis of these MPDs. Kae Normandeau Administrative Manager Neuroscience Research Program SR440 KIAM Building P: 204-318-2569 E: kae.normandeau(a)umanitoba.ca<mailto:kae.normandeau@umanitoba.ca> This email and any attachments may contain confidential, personal and/or privileged information intended for a specific individual and purpose. If you are not the intended recipient, you are hereby notified that any disclosure, copying, retaining, distribution, access, use or modification of the contents of this e-mailed information is strictly prohibited. If you receive this communication in error, please notify the sender immediately and delete or destroy the email message and any attachments or copies. ****************************************** [cid:image003.jpg@01D159B3.9F0B9710]<http://www.manitobaneuroscience.ca/> [cid:image007.png@01D29326.7E26D480]<https://www.facebook.com/manitobaneuroscience/?fref=ts> [cid:image009.jpg@01D29326.7E26D480] <https://www.instagram.com/manitobaneuroscience/> [cid:image010.png@01D29326.7E26D480] <https://twitter.com/manitobaneuro>

1 0

BAW SPECIAL EVENT - In Conversation with Dr. Pierre Marquet
by Kae Normandeau 12 Mar '18

12 Mar '18

[cid:image001.jpg@01D158FE.B69B8D00] B R A I N A W A R E N E S S W E E K SPECIAL EVENT: D A T E Wednesday, March 14th, 2018 7:00pm L O C A T I O N McNally Robinson Bookstore 4000-1120 Grant Avenue IN CONVERSATION WITH DR. PIERRE MARQUET C A N A D A EXCELLENCE R E S E A R C H C H A I R NEUROPHOTONICS T O P I C Identification of a childhood risk syndrome of major psychiatric diseases: a step towards their prevention. Psychiatrist, Pierre Marquet also holds a Master of physical engineering from Ecole Polytechnique Fédérale de Lausanne, Switzerland and an M.D./Ph.D. in neurophotonics from University of Lausanne. Recognized worldwide for his pioneering work on digital holographic microscopy, he is a professor of psychiatry at Université Laval and the chairholder of the CERC in Neurophotonics. He is also the director of the International Joint Research Unit (IJRU) in neurodevelopment and child psychiatry. The goal of this IJRU is to identify new risk biomarkers and endophenotypes to define childhood risk syndromes of major psychiatric disorders including schizophrenia, bipolar disorders and major depression disorder with the help of neurophotonics tools. He is the author or co-author of more than 140 scientific publications (6500 citations, h-index 36), of many patents and is the co-founder of three technological start-up companies. Kae Normandeau Administrative Manager Neuroscience Research Program SR440 KIAM Building P: 204-318-2569 E: kae.normandeau(a)umanitoba.ca<mailto:kae.normandeau@umanitoba.ca> This email and any attachments may contain confidential, personal and/or privileged information intended for a specific individual and purpose. If you are not the intended recipient, you are hereby notified that any disclosure, copying, retaining, distribution, access, use or modification of the contents of this e-mailed information is strictly prohibited. If you receive this communication in error, please notify the sender immediately and delete or destroy the email message and any attachments or copies. ****************************************** [cid:image003.jpg@01D159B3.9F0B9710]<http://www.manitobaneuroscience.ca/> [cid:image007.png@01D29326.7E26D480]<https://www.facebook.com/manitobaneuroscience/?fref=ts> [cid:image009.jpg@01D29326.7E26D480] <https://www.instagram.com/manitobaneuroscience/> [cid:image010.png@01D29326.7E26D480] <https://twitter.com/manitobaneuro>

1 0

BAW Special Lecture - Dr. Pierre Marquet | Wednesday, March 14th
by Kae Normandeau 12 Mar '18

12 Mar '18

[cid:image001.jpg@01D158FE.B69B8D00] SPECIAL LECTURE: B R A I N A W A R E N E S S W E E K D A T E Wednesday, March 14th, 2018 12Noon *Followed by a Trainee Lunch in SR415, KIAM L O C A T I O N Theatre C, BMSB S P E A K E R D R . PIERRE MARQUET C A N A D A EXCELLENCE R E S E A R C H C H A I R NEUROPHOTONICS T O P I C Neurophotonics to Intercept the Emergence of Major Psychiatric Disorders Major psychiatric disorders (MPDs) including psychosis and mood disorders affect *4% of the population. MPDs have chronic courses since their diagnoses, solely based on clinical symptoms, are very late and thus better treatments are only palliative. The successful development of early treatment and primary prevention is largely impeded by the lack of reliable risk biomarkers or endophenotypes (B/Es). This is a critical issue since MPDs have a neurodevelopmental origin and early intervention can improve outcomes. >From a developmental standpoint, the identification of B/Es in patients with MPDs and in their offspring at genetic risk will play a pivotal role in the definition of childhood risk syndromes and their corresponding abnormal trajectories. This approach is particularly relevant given that high-risk children carry many of the indicators of brain dysfunctions that adult patients have. Within this framework, I will present how the development of new multimodal optical imaging techniques in combination with stem cell technologies, including human induced pluripotent stem cells approaches, can contribute to identifying new cellular B/Es relevant both to define childhood risk syndromes and to determine cellular processes likely to be involved in the pathogenesis of these MPDs. Kae Normandeau Administrative Manager Neuroscience Research Program SR440 KIAM Building P: 204-318-2569 E: kae.normandeau(a)umanitoba.ca<mailto:kae.normandeau@umanitoba.ca> This email and any attachments may contain confidential, personal and/or privileged information intended for a specific individual and purpose. If you are not the intended recipient, you are hereby notified that any disclosure, copying, retaining, distribution, access, use or modification of the contents of this e-mailed information is strictly prohibited. If you receive this communication in error, please notify the sender immediately and delete or destroy the email message and any attachments or copies. ****************************************** [cid:image003.jpg@01D159B3.9F0B9710]<http://www.manitobaneuroscience.ca/> [cid:image007.png@01D29326.7E26D480]<https://www.facebook.com/manitobaneuroscience/?fref=ts> [cid:image009.jpg@01D29326.7E26D480] <https://www.instagram.com/manitobaneuroscience/> [cid:image010.png@01D29326.7E26D480] <https://twitter.com/manitobaneuro>

1 0

Visit of Dr. David Eidelberg
by networking＠manitobaneuroscience.ca 12 Mar '18

12 Mar '18

/Sent on behalf of Dr. Ji Hyun Ko Dear all, Dr. David Eidelberg is visiting Winnipeg and offering two seminars (one at Bannatyne campus and one at Fort Garry campus). Please see the attached posters. Best, Ji Hyun Ji Hyun Ko, PhD Assistant Professor Department of Human Anatomy and Cell Science Max Rady College of Medicine, Rady Faculty of Health Sciences University of Manitoba Principal Investigator Neuroscience Research Program Kleysen Institute for Advanced Medicine Health Science Centre Mailing Address: SR452 - 710 William Avenue Winnipeg, MB R3E 0Z3 Canada Tel: +1-204-318-2566 Email: ji.ko(a)umanitoba.ca <mailto:ji.ko@umanitoba.ca> http://www.kolabneuro.com/ ****************************************** <http://www.manitobaneuroscience.ca/> <https://www.facebook.com/manitobaneuroscience/?fref=ts> <https://www.instagram.com/manitobaneuroscience/> <https://twitter.com/manitobaneuro>

1 0

Visit of Dr. David Eidelberg
by info＠manitobaneuroscience.ca 05 Mar '18

05 Mar '18

/Sent on behalf of Dr. Ji Hyun Ko Dear all, As part of Biomedical Engineering Seminar Series (4pm, Fort Garry campus), I invited Dr. David Eidelberg (March 15th, 2018). He will also give a talk in the Bannatyne campus at noon. David Eidelberg, MD is the Susan and Leonard Feinstein Professor of Neurology and Neuroscience, and has served as Director of the Center for Neurosciences at The Feinstein Institute for Medical Research since its founding in 2001. A neurologist and neuroscientist, he is widely regarded for his pioneering work on network dysfunction in brain disease. Under his direction, the Eidelberg group has developed innovative computational approaches using imaging to identify specific network biomarkers for a variety of brain disorders ranging from Parkinson's, Alzheimer's, and Huntington's disease to Dystonia, Tourette's syndrome and obsessive compulsive disorder. Disease-related networks are being assayed in individual patients to distinguish between clinically similar "look-a-like" conditions, monitor disease progression, and evaluate new treatments for these disorders. Dr. Eidelberg received his medical degree from Harvard Medical School. He completed his residency in neurology there, followed by postdoctoral training in brain imaging in London and New York. Dr. Eidelberg has authored over 250 peer-reviewed original articles, 100 reviews and editorials, and an edited volume (Imaging in Parkinson's Disease, Oxford University Press, 2011). He currently serves on the editorial boards of several major journals, and is editor-in-chief (with Professor Jean-Marc Leger) of Current Opinion in Neurology. He is a scientific advisor to the National Institutes of Health (NIH), U.S. Department of Defense, the Michael J. Fox Foundation, and the Collaborative Center for X-linked Dystonia Parkinsonism at Massachusetts General Hospital. Now, I am trying to develop an itinerary for his visit. Please email me (ji.ko(a)umanitoba.ca <mailto:ji.ko@umanitoba.ca> ) if any of you are interested in meeting with him in-person with your available time on March 15th. Best, Ji Hyun Ji Hyun Ko, PhD Assistant Professor Department of Human Anatomy and Cell Science Max Rady College of Medicine, Rady Faculty of Health Sciences University of Manitoba Principal Investigator Neuroscience Research Program Kleysen Institute for Advanced Medicine Health Science Centre Mailing Address: SR452 - 710 William Avenue Winnipeg, MB R3E 0Z3 Canada Tel: +1-204-318-2566 Email: ji.ko(a)umanitoba.ca <mailto:ji.ko@umanitoba.ca> http://www.kolabneuro.com/ ****************************************** <http://www.manitobaneuroscience.ca/> <https://www.facebook.com/manitobaneuroscience/?fref=ts> <https://www.instagram.com/manitobaneuroscience/> <https://twitter.com/manitobaneuro>

1 0